Author

T. KARANTANOS

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. R. Moliterno· 1 shared A. Sandhu· 1 shared B. Paun· 1 shared B. Perkins· 1 shared C. Bonifant· 1 shared C. Danchik· 1 shared C. Esteb· 1 shared C. Schill· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. R. Moliterno

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

S. Karanika, J. Gordy, P. Neupane, T. KARANTANOS, J. Castillo, D. Quijada, K. Comstock, A. Sandhu, Y. Hui, S. Ayeh, R. Tasneen, S. Krug, C. Danchik, T. Wang, C. Schill, , P. Karakousis

This paper develops a DNA vaccine targeting dendritic cells that enhances isoniazid efficacy against tuberculosis by inducing strong immune responses and reducing Mtb burden.

bioRxiv · Apr 19, 2022Immunology

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia

T. KARANTANOS, P. Teodorescu, B. Perkins, I. Christodolou, C. Esteb, R. Varadhan, E. Helmenstine, T. Rajkhowa, B. Paun, C. Bonifant, W. B. Dalton, L. P. Gondek, A. R. Moliterno, M. J. Levis, G. Ghiaur, R. J. Jones

This study identifies CCRL2 as a mediator of MDS and secondary acute myeloid leukemia growth through JAK2/STAT signaling, with potential therapeutic implications.

bioRxiv · Jul 29, 2021Cancer Biology